The FDA lifted its clinical hold on a study evaluating BPX-601 and rimiducid for patients with previously treated metastatic pancreatic or prostate cancers, according to a press release from the agent’s manufacturer.
BPX-601 (Bellicum Pharmaceuticals) is an autologous chimeric antigen receptor T-cell therapy that targets tumor cells expressing high levels of prostate stem cell antigen (PSCA). Read more . . .